Curis Inc (CRIS) is a publicly traded Healthcare sector company. As of July 7, 2026, CRIS trades at $5.35 with a market cap of $11.58M and a P/E ratio of -0.43. CRIS moved -10.94% today. Year to date, CRIS is -73.81%; over the trailing twelve months it is -84.80%. Its 52-week range spans $3.61 to $94.00. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces CRIS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Curis Enrolls First Six Patients, Targets July Dosing and December Data: In its TakeAim CLL study, Curis has consented the first six patients and now targets dosing five CLL patients by late July 2026. The biotech expects initial combination therapy data with emavusertib and zanubrutinib in December 2026.
| Metric | Value |
|---|---|
| Price | $5.35 |
| Market Cap | $11.58M |
| P/E Ratio | -0.43 |
| EPS | $-0.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $94.00 |
| 52-Week Low | $3.61 |
| Volume | 203.47K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.06M |
| Net Income | $-21.16M |
| Gross Margin | 0.00% |
2 analysts cover CRIS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.